(Q40587923)

21 September 2017

Management of infection in cancer patients. studies of the EORTC International Antimicrobial Therapy Group (IATG). (English)

1 reference

21 September 2017

C Viscoli

1

1 reference

PubMed ID

11858971

21 September 2017

EORTC International Antimicrobial Therapy Group

series ordinal

2

1 reference

21 September 2017

1 March 2002

1 reference

European Journal of Cancer

21 September 2017

1 reference

21 September 2017

38 Suppl 4

1 reference

21 September 2017

S82-7

1 reference

Planned progressive antimicrobial therapy in neutropenic patients

21 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900461-0

7 January 2021

Combination of amikacin and carbenicillin with or without cefazolin as empirical treatment of febrile neutropenic patients. The International Antimicrobial Therapy Project Group of the European Organization for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900461-0

7 January 2021

Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900461-0

7 January 2021

Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900461-0

7 January 2021

Gram-positive bacteraemia in granulocytopenic cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900461-0

7 January 2021

Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of C

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900461-0

7 January 2021

Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The International Antimicrobial Therapy Cooperative Group of t

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900461-0

7 January 2021

Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Tre

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900461-0

7 January 2021

Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Re

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900461-0

7 January 2021

Oral versus Intravenous Empirical Antimicrobial Therapy for Fever in Patients with Granulocytopenia Who Are Receiving Cancer Chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900461-0

7 January 2021

Trimethoprim-sulfamethoxazole in the prevention of infection in neutropenic patients. EORTC International Antimicrobial Therapy Project Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900461-0

7 January 2021

Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. The International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900461-0

7 January 2021

A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Can

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900461-0

7 January 2021

Association between antifungal prophylaxis and rate of documented bacteremia in febrile neutropenic cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900461-0

7 January 2021

An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900461-0

7 January 2021

The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900461-0

7 January 2021

From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900461-0

7 January 2021

10.1016/S0959-8049(01)00461-0

Identifiers

DOI

1 reference

21 September 2017

1 reference

PubMed ID

11858971